SpectraCure AB (publ) (SPEC.ST)
SEK 1.82
(-0.22%)
SEK 1.82
(-0.22%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 12.12 Million SEK | -59.61% |
| 2022 | 30.02 Million SEK | 16.36% |
| 2021 | 25.8 Million SEK | 37.14% |
| 2020 | 18.81 Million SEK | 11.3% |
| 2019 | 16.9 Million SEK | 42.03% |
| 2018 | 11.9 Million SEK | 13.26% |
| 2017 | 10.5 Million SEK | 29.31% |
| 2016 | 8.12 Million SEK | 19.88% |
| 2015 | 6.77 Million SEK | 31.01% |
| 2014 | 5.17 Million SEK | -26.32% |
| 2013 | 7.02 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 5.38 Million SEK | 41.54% |
| 2024 Q1 | 5.62 Million SEK | -6.64% |
| 2023 FY | 21.36 Million SEK | -28.83% |
| 2023 Q1 | 9.78 Million SEK | 5.1% |
| 2023 Q3 | 6.28 Million SEK | -18.43% |
| 2023 Q2 | 7.69 Million SEK | -21.3% |
| 2023 Q4 | 6.02 Million SEK | -4.12% |
| 2022 Q1 | 6.8 Million SEK | -14.28% |
| 2022 Q3 | 6.09 Million SEK | -22.55% |
| 2022 Q4 | 9.3 Million SEK | 52.72% |
| 2022 FY | 30.02 Million SEK | 16.36% |
| 2022 Q2 | 7.87 Million SEK | 15.63% |
| 2021 Q4 | 7.94 Million SEK | 27.53% |
| 2021 Q3 | 6.22 Million SEK | -6.64% |
| 2021 Q2 | 6.66 Million SEK | 34.24% |
| 2021 Q1 | 4.96 Million SEK | -23.06% |
| 2021 FY | 25.8 Million SEK | 37.14% |
| 2020 Q2 | 5.14 Million SEK | 22.63% |
| 2020 Q4 | 6.45 Million SEK | 113.74% |
| 2020 FY | 18.81 Million SEK | 11.3% |
| 2020 Q1 | 4.19 Million SEK | -17.36% |
| 2020 Q3 | 3.02 Million SEK | -41.26% |
| 2019 FY | 16.9 Million SEK | 42.03% |
| 2019 Q4 | 5.07 Million SEK | 38.28% |
| 2019 Q3 | 3.67 Million SEK | -24.31% |
| 2019 Q2 | 4.84 Million SEK | 46.45% |
| 2019 Q1 | 3.31 Million SEK | -23.43% |
| 2018 Q4 | 4.32 Million SEK | 61.95% |
| 2018 Q1 | 28 Thousand SEK | -99.1% |
| 2018 Q2 | 4.88 Million SEK | 17328.57% |
| 2018 Q3 | 2.67 Million SEK | -45.29% |
| 2018 FY | 11.9 Million SEK | 13.26% |
| 2017 Q1 | 2.23 Million SEK | -2.59% |
| 2017 FY | 10.5 Million SEK | 29.31% |
| 2017 Q2 | 2.55 Million SEK | 14.24% |
| 2017 Q3 | 2.61 Million SEK | 2.25% |
| 2017 Q4 | 3.09 Million SEK | 18.51% |
| 2016 Q3 | 1.54 Million SEK | -30.1% |
| 2016 Q1 | 2.03 Million SEK | 2.58% |
| 2016 Q4 | 2.29 Million SEK | 49.15% |
| 2016 FY | 8.12 Million SEK | 19.88% |
| 2016 Q2 | 2.2 Million SEK | 8.48% |
| 2015 Q1 | 675.82 Thousand SEK | -64.29% |
| 2015 Q4 | 1.98 Million SEK | 36.54% |
| 2015 Q3 | 1.45 Million SEK | -45.72% |
| 2015 Q2 | 2.67 Million SEK | 295.39% |
| 2015 FY | 6.77 Million SEK | 31.01% |
| 2014 FY | 5.17 Million SEK | -26.32% |
| 2014 Q1 | 906.59 Thousand SEK | 0.0% |
| 2014 Q2 | 797.08 Thousand SEK | -12.08% |
| 2014 Q3 | 1.57 Million SEK | 97.94% |
| 2014 Q4 | 1.89 Million SEK | 19.97% |
| 2013 FY | 7.02 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 85.361% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 98.018% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 98.018% |
| Arcoma AB | 53.25 Million SEK | 77.225% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -144.073% |
| BICO Group AB (publ) | 2.84 Billion SEK | 99.574% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 94.237% |
| CellaVision AB (publ) | 295.99 Million SEK | 95.903% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | 82.405% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -826.379% |
| C-Rad AB (publ) | 3.8 Million SEK | -219.158% |
| Duearity AB (publ) | 21.58 Million SEK | 43.813% |
| Dignitana AB (publ) | 74.73 Million SEK | 83.772% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -349.185% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.887% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | 33.467% |
| Iconovo AB (publ) | 63.35 Million SEK | 80.857% |
| Integrum AB (publ) | 90.57 Million SEK | 86.609% |
| Luxbright AB (publ) | 23.09 Million SEK | 47.476% |
| Mentice AB (publ) | 237.06 Million SEK | 94.884% |
| OssDsign AB (publ) | 175.6 Million SEK | 93.093% |
| Paxman AB (publ) | 133.8 Million SEK | 90.936% |
| Promimic AB (publ) | 48.55 Million SEK | 75.021% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 92.531% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 82.668% |
| ScandiDos AB (publ) | 61.03 Million SEK | 80.13% |
| Sectra AB (publ) | 39.06 Million SEK | 68.953% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 93.051% |
| Senzime AB (publ) | 141.51 Million SEK | 91.43% |
| Stille AB | 87.21 Million SEK | 86.095% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 99.782% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 97.249% |